Does Certain Cyp3a Substrates Interact with Mitotane?
Certain Cyp3a Substrates and Mitotane have a major drug interaction according to U.S. FDA drug labeling data. Mitotane is a strong CYP3A inducer that may decrease levels of CYP3A substrates, potentially leading to serious therapeutic failures. Avoid concomitant use or modify substrate dosage. The mechanism involves cyp3a induction. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Major
- Mitotane Class
- Cytochrome P450 3A4 Inducers
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Certain Cyp3a Substrates and Mitotane occurs because cyp3a induction. Clinically, this means mitotane is a strong cyp3a inducer that may decrease levels of cyp3a substrates, potentially leading to serious therapeutic failures. avoid concomitant use or modify substrate dosage. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.
What To Tell Your Doctor or Pharmacist
If you are taking Certain Cyp3a Substrates and your doctor is considering prescribing Mitotane (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider